ABSTRACT OF THE DISCLOSURE

The invention relates to the fields of inflammation and immunology and, more specifically, to the field of chemokines and receptors therefor, and their role in neurodegenerative or neuroinflammatory disease. The invention provides a method for identifying a candidate drug compound for the treatment of inflammatory or degenerative brain disease comprising testing the compound for its capacity to modulate or mimic MCP-1 binding with a chemokine receptor capable of being expressed on brain glial cells, the receptor known in the mouse as L-CCR or in humans as CRAM-B.